产能狙击：在美国市场，礼来已成功克服了早期的供应链难题，使得Zepbound（替尔泊肽）的所有剂量在美国市场上都可以得到供应。相比之下，诺和诺德在向美国市场供应Wegovy（司美格鲁肽）方面仍然面临困难。

按照协议，礼来公司将启动一项“真实世界”研究，旨在了解替西帕肽（tirzepatide，其Zepbound和Mounjaro药物背后的GLP-1受体激动剂药物）如何影响减肥、糖尿病预防和肥胖相关并发症的预防，以更好地为英国国家卫生服务局（NHS）应对 ...

周五， 礼来 (LLY.US)股价震荡上行，截至发稿，上涨1.18%，报921.435美元。消息面上，礼来公司首席执行官周五表示，减肥药Zepbound有望明年在日本获批。

智通财经APP获悉，周五，礼来 (LLY.US)股价震荡上行，截至发稿，上涨1.18%，报921.435美元。消息面上，礼来公司首席执行官周五表示，减肥药Zepbound有望明年在日本获批。

周四,Truist Securities更新了制药公司礼来(NYSE:LLY)的财务模型,导致该公司股票的目标价上调。目标价从此前的1,000.00美元上调至1,033.00美元,同时该公司维持对该股票的买入评级。

【礼来CEO称减肥药Zepbound有望明年在日本获批】礼来公司首席执行官周五表示，减肥药Zepbound有望明年在日本获批。

2, 2024, the agency announced that the shortage has been resolved for the medicine tirzepatide, the active ingredient in Mounjaro and Zepbound. Despite the soaring demand and limited supply of ...

branded as Zepbound. Writing for the U.K.’s The Telegraph newspaper, Secretary of State for Health & Social Care Wes Streeting announced the five-year real-world study on Monday. It aims to ...

A ruling issued Friday in the U.S. District Court for the Northern District of Texas permits the makers of compounded versions of tirzepatide, the active ingredient in Zepbound and Mounjaro ...

Leerink Partners维持礼来(NYSE: LLY)股票"跑赢大市"评级，目标价保持在$990.00不变。该公司在预期礼来第三季度业绩时调整了其财务模型。

And that's the company's weight loss drugs. Lilly sells the compound tirzepatide under two different names -- Mounjaro for type 2 diabetes and Zepbound for weight loss. But doctors have prescribed ...

The Food and Drug Administration (FDA) recently removed Eli Lily's weight-loss drug from its shortage list, which some industry officials and medical experts argue will complicate access for some ...